Head-To-Head Analysis: Aerie Pharmaceuticals (AERI) vs. Affimed (AFMD)

Aerie Pharmaceuticals (NASDAQ: AERI) and Affimed (NASDAQ:AFMD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aerie Pharmaceuticals and Affimed, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerie Pharmaceuticals 0 1 13 0 2.93
Affimed 0 2 1 0 2.33

Aerie Pharmaceuticals currently has a consensus price target of $73.79, suggesting a potential upside of 34.52%. Affimed has a consensus price target of $6.50, suggesting a potential upside of 390.57%. Given Affimed’s higher probable upside, analysts clearly believe Affimed is more favorable than Aerie Pharmaceuticals.

Volatility & Risk

Aerie Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Affimed has a beta of 3.48, suggesting that its share price is 248% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aerie Pharmaceuticals and Affimed’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerie Pharmaceuticals N/A N/A -$99.05 million ($3.35) -16.37
Affimed $6.88 million 8.60 -$35.65 million ($0.78) -1.70

Affimed has higher revenue and earnings than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

40.4% of Affimed shares are held by institutional investors. 9.4% of Aerie Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares Aerie Pharmaceuticals and Affimed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aerie Pharmaceuticals N/A -86.87% -41.89%
Affimed -1,074.37% -72.94% -57.13%


Affimed beats Aerie Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Affimed Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit